TD101

DB06596InvestigationalSmall molecule

TD101, a small interfering RNA (siRNA) designed for the treatment of pachyonychia congenita.

Mechanism: Pharmacologically active on Keratin, type II cytoskeletal 6A
Curator reviewed
Primary indication: Investigated for use/treatment in skin infections/disorders.Curator reviewed
Code names: TD101

Resolves to

Targets

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with TD101, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.